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October 2009966 AbstractsResults: During this period, 6404 CEAs were performed for asymp-
tomatic disease; 102 (2%) for stenoses of 60%-69%, 758 (12%) of 70%-79%
stenosis, 2263 (35%) for 80%-89% stenosis, and 3281 (51%) for 90%-99%
stenosis. Risk factors were similar in all groups. Shunt utilization was higher
in the 60%-69% stenosis group than the others. In the 60%-69% group there
were no strokes and no deaths, in the 70%-79% group there were two (0.3%)
deaths and two (0.6%) strokes. In the 80%-89% group there were 12 (0.5%)
deaths, 11 permanent neurologic deficits, and two temporary neurologic
deficits (0.6%). In the 90%-99% group, there were 23 (0.7%) mortalities, five
(0.2%) temporary neurological deficits (TND), and nine (0.3%) permanent
strokes. The most common non-neurologic complication was postoperative
hematoma at 1.4% and was consistent throughout all groups. Mean fol-
low-up averaged 48 months.
Conclusions: Patients presenting with moderate 60% to 69% stenoses
can be treated safely with carotid endarterectomy. All asymptomatic patients
over 60% stenosis had an acceptably low mortality and morbidity in this
series.
Durability of Infrainguinal Interventions in Patients with Severely
Disabling Claudication and TASC II C and D Femoropopliteal Disease
Dosluoglu HH, Lall P, Harris LM, Dryjski ML
Objectives: Durability of open and endovascular interventions on
patients with disabling claudication is a major concern, especially in those
with complex anatomy needing infrainguinal reconstructions. The goal of
our study was to compare our results of bypass versus endovascular inter-
ventions in a consecutive patient series and to determine effectiveness of
treatment modality.
Methods: All patients who presented with severely disabling claudica-
tion (Rutherford 3) with TASC II C or D disease, who underwent bypass, or
infrainguinal endovascular (EV) interventions following failure of medical
management between June 2001 and December 2008 were included.
Results:There were 56 patients in the EV group, and 56 patients in the
open group. The comorbidities were similar, except there were more active
smokers (68% vs. 46%, P .035) and prior ipsilateral revascularizations (38%
vs. 7%, P  .001) in the open group. Fifty-nine percent of bypasses were
performed using polytetrafluoroethylene (PTFE). There were no 30-day
postoperative mortalities. There were four superficial infections, one deep
infection (necessitating graft removal), and one perigraft seroma in the open
group. Technical success was 95% in the EV group. Length of stay was
significantly less in the EV group (1.0  1.3 vs. 5.1  4.1 days, P  .001).
The mean ankle-brachial index (ABI) increased from 0.55 to 0.94, similar in
both groups. The mean follow-up was 29 22 months. Primary, secondary
patency, sustained clinical success rates (clinical improvement, freedom from
target extremity revascularization (TER]), secondary clinical success (with
TER) were similar (Table I), with a 36-month survival rate of 91 4%. Only
one patient had an amputation in the open group at 32 months. Fifteen
patients (27%) in open and 20 patients (36%) in EV group required ipsilat-
eral reinterventions (Table II; P  .419).
Conclusions: Clinical benefit following endovascular and open inter-
ventions in patients with severely disabling claudication and TASC II C or D
femoropopliteal disease is similar at three years. The clinical improvement
without additional procedures is achieved only in half, and TER is required
in about a third of the patients. Aggressive medical management of claudi-
cation is warranted before any (open or endovascular) interventions are
planned, and patients should be informed of the expected outcomes.
Table I. Patency rates and sustained and secondary
clinical success rates
PP SP SusClSuc SecClSuc
12 mo 36 mo 12 mo 36 mo 12 mo 36 mo 12 mo 36 mo
Open 79%  6% 59%  8% 82%  6% 71%  8% 77%  6% 58%  8% 85%  5% 75%  7%
EV 69%  7% 54%  8% 86%  5% 69%  9% 67%  7% 48%  8% 92%  4% 80%  8%
P .162 .942 .120 .387
EV, Endovascular; PP, primary patency; SecCLSuc, secondary clinical suc-
cess; SP, secondary patency; SusClSuc, sustained clinical success.Table II. Reinterventions in open and EV-treated groups
Reinterventions Open EV
Thrombolysis  PTA/S 6 8
Repeat bypass 5 7
EV recanalization 2 1
Inflow/runoff EV intervention 2 8
Contralateral revascularization 5 7
Contralateral amputation 2 0
EV, Endovascular; PTA/S, percutaneous transluminal angioplasty/stent.
Salvage after Failed Surgical Bypass: Effectiveness of Endovascular
Recanalization of Native Lower Extremity Arterial Occlusions
Dayal R , Graham AR , Khan H, et al
Objectives:The purpose of this study was to determine the outcome of
endovascular interventions of the native circulation after failed lower extrem-
ity bypass grafting.
Methods: A prospective registry encompassing all patients treated for
lower extremity atherosclerotic disease from May 2004 to September 2008
was established. Patients were followed with duplex ultrasound and ankle-
brachial index/pulse volume recording (ABI/PVR) at one, three, six, and
12 months and annually. Patients treated after failed lower extremity bypass
grafting were identified and angiogram, duplex, and ABI data abstracted.
Patients with similar comorbidities and lesion characteristics not treated with
prior bypass grafting were used as comparison. Statistical analysis was per-
formed using Kaplan-Meier and log-rank analysis.
Results: One thousand nine hundred and thirty eight lower extremity
arterial lesions were treated in 826 patients. Seventy-four arterial lesions in 39
patients were treated in those who had undergone prior bypass grafting (BPG).
Indications were claudication (n  16, 38.5%), rest pain (n  8, 17.9%), and
tissue loss (n  15, 43.6%). Prior bypass were femoral to popliteal (71.8%),
femoral to tibial (25.6%), and external iliac to popliteal (2.6%). Mean follow-up
was 13.7 11.5months. Comparison to a corresponding group of non-bypass
graft patients (NBPG) revealed that there was no significant difference in
primary, assisted primary, secondary patencies, or limb salvage in patients
treated with prior BPG (Table I) when the indication for treatment was critical
limb ischemia (CLI). In contrast, comparison to a corresponding group of
NBPG revealed that there was significant decrease in primary, assisted primary,
and secondary patency in patients treated with prior BPG (Table II) when the
indication for treatment was claudication. This difference persisted even when
corrected for comorbidities and lesion characteristics. Lesion length, percent
stenosis, and percent chronic total occlusion were 162.7 139.7 and 130.3
56.9 (P .21), 88.4 11.0 and 90.1 12.1 (P .47), 34.4% and 49.7% (P
.12) for BPG and NBPG lesions, respectively.
Conclusions: Endovascular salvage of native arterial occlusions after
failed surgical bypass achieves acceptable patency and limb salvage in patients
with CLI. Conversely, patients with claudication that are subsequently
treated with endovascular methods have poor long-term patency and require
multiple endovascular interventions to maintain patency.
Table I. Patency and limb salvage rates in CLI patients
treated with endovascular modalities
6 mo 12 mo 18 mo 24 mo 30 mo
Primary patency BPG 74.6  7.3 51.2  8.9 33.4  9.3 33.4  9.3 11.1  9.6
Primary patency
No BPG
69.2  3.7
P  .59
51.0  4.4
P  .95
42.1  4.6
P  .68
35.2  4.8
P  .860
35.2  4.8
P  .556
Primary assisted
patency BPG
83.2  6.3 58.8  9.0 49.3  9.8 49.3  9.8 49.3  9.8
Primary assisted
patency
No BPG
73.0  3.6
P  .26
60.3  4.3
P  .90
53.1  4.7
P  .98
45.6  5.1
P  .78
43.7  5.2
P  .74
Secondary patency
BPG
83.1  6.3 72.0  8.1 61.3  9.8 61.3  9.8 61.3  9.8
Secondary patency
No BPG
78.2  3.3
P  .57
71.7  3.9
P  .88
64.5  4.5
P  .95
57.9  5.1
P  .86
55.9  5.3
P  .82
Limb salvage BPG 85.4  6.0 76.9  7.9 76.9  7.9 76.9  7.9 76.9  7.9
Limb salvage
No BPG
86.1  2.8
P  .89
80.2  3.5
P  .75
77.6  3.9
P  .88
75.4  4.4
P  .94
71.9  5.4
P  .98
BPG, Bypass grafting; CLI, critical limb ischemia.
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with endovascular modality
6 mos 12 mos 18 mos 24 mos 30 mos
Primary patency
BPG
65.6  8.4 51.6  9.1 25.8  8.3 22.1  7.9 22.1  7.9
Primary patency
No BPG
93.7  2.2 75.4  4.3 64.7  4.9 60.2  5.2 58.1  5.5
Primary patency P
Values
.0001 .0001 .0001 .0001 .0001
Primary assisted
patency BPG
87.3  6.0 75.9  8.0 70.5  9.1 65.1  9.9 65.1  9.9
Primary assisted
patency No
BPG
96.8  1.6 90.9  2.8 87.1  3.4 83.8  4.0 79.5  4.8
Primary assisted
patency P
Values
.031 .025 .031 .023 .039
Secondary patency
BPG
90.4  5.3 90.4  5.3 83.9  7.9 77.5  9.6 77.5  9.6
Secondary patency
No BPG
98.4  1.1 96.4  1.8 94.8  2.4 91.3  3.3 91.3  3.3
Secondary patency
P values
.03 .13 .06 .05 .05
BPG, Bypass grafting.
Long-Term Outcomes of Diabetic Patients Undergoing Endovascular
Infrainguinal Interventions
Abularrage CJ, Conrad MF, Crawford RS, et al
Objectives: Diabetes has traditionally predicted poor outcomes after
lower extremity revascularization for peripheral vascular disease (PVD). The
purpose of this studywas to assess the influence of diabetes on long-termoutcomes
of percutaneous translumininal angioplasty (PTA) in patients with PVD.
Methods: From January 2002 to December 2007, 1075 patients
underwent PTA. Endpoints including primary patency (PP), assisted pa-
tency (AP), limb salvage, and survival were evaluated in the entire cohort, as
well as in diabetic (DM) and non-diabetic (non-DM) patients, using Kaplan-
Meier and Cox regression analyses.
Results: There were 533 DM and 542 non-DM patients. Significant
clinical and demographic features are summarized in the Table. Median
follow-up was 34 months. In the entire cohort, the five-year PP was 42% 
2.4%, AP was 81%  2.0%, limb salvage was 89%  1.6%, and survival was
60%  2.2%. On univariate analysis, diabetes was associated with inferior
five-year PP (DM: 37%  3.4% vs. non-DM: 46%  3.3%, P .009), limb
salvage (84% 2.6% vs. 93% 1.8%, P .0001), and survival (52% 3.2%
vs. 68%  2.9%, P  .0001). Assisted patency did not differ between DM
and non-DM (P  .18). In the entire cohort, DM (1.25; [1.01-1.54]; P 
.04), single vessel peroneal runoff (1.54; [1.16-2.08]; P .003), and dialysis
(1.59; [1.10-2.33]; P  .02) were associated with decreased PP on multi-
variate analysis. DM was also an independent predictor of death after PTA
(1.32; [1.02-1.67]; P  .03). Critical limb ischemia and dialysis were the
only variables on multivariate analysis to predict both limb loss and death.
Conclusions: Diabetes is an independent predictor of decreased PP
and death after PTA. Although acceptable assisted patency rates can be
achieved with close surveillance and reintervention, long-term limb salvage
and survival remain inferior in the diabetic population due to a more severe
cardiovascular risk profile and clinical presentation.
Table. Clinical and demographic features
DM Non-DM P
Male gender 368 (69%) 323 (60%) .001
Coronary artery disease 368 (69%) 293 (54%) .0001
Dialysis 56 (11%) 22 (4%) .0001
Critical limb ischemia 284 (53%) 155 (24%) .0001
Single vessel runoff 205 (38%) 126 (23%) .0001
Multi-level intervention 125 (23%) 83 (15%) .0007
Isolated tibial intervention 58 (11%) 31 (6%) .002
DM, Diabetic.
Outcomes of Endoluminal Re-intervention for Recurrent Disease after
Percutaneous Iliac Angioplasty and Stenting
Davies MG, Bismuth J, Naoum J, Houssan H, Peden EK, Lumsden ABObjectives: Endovascular therapy for symptomatic atherosclerotic iliac
artery stenosis is common but is associated with a significant restenosis rate.This study evaluates the outcomes of percutaneous therapy for symptomatic
restenosis (50% on angiography) after iliac intervention at a national
academic medical center.
Methods: We performed a retrospective analysis of records from
patients who underwent endovascular intervention for symptomatic athero-
sclerotic iliac artery stenosis and were followed by duplex ultrasound be-
tween January 1990 and January 2009.
Results: Eight hundred seventy-nine patients underwent 1444 iliac
artery interventions. One hundred fifty-six vessels restenosed with an actuarial
restenosis rate of 20%  2% at five years. Presenting symptoms, angioplasty
alone, a concurrent occluded superficial femoral artery (SFA), and increasing
complexity of the iliac intervention were associated with restenosis. One
hundred forty of these restenoses (90%) were associated with recurrent
symptoms. One hundred nine (78%) underwent repeat angioplasty and 31
underwent bypass surgery. The remainder were observed. The 109 percu-
taneous interventions were performed in  patients (57%male; average age,
58 years; range, 38-87 years). Eighty-five percent had hypertension, 76%
had hyperlipidemia, 54% had metabolic syndrome, 41% were considered
diabetic, and 17% had chronic renal insufficiency (eGFR60). There was a
1% technical failure rate. Comparisons of demographics, presenting symp-
toms, and outcomes between those patients undergoing intervention for a
primary lesion and those for a recurrent lesion are shown in the Table. By
Cox proportional hazards and multivariate analysis, presenting symptoms,
female gender, and eGFR 60ml negatively influenced cumulative patency
of recurrent lesions. An occluded SFA but not TASC lesion negatively
influences cumulative patency of recurrent lesions. Restenosis and recurrent
symptoms were tightly associated
Conclusions: Percutaneous re-intervention for iliac artery restenosis is
safe and effective with equivalent outcomes to primary intervention. The
patients are more likely to be younger and of female gender than patients
presenting for primary intervention. Both patency and functional outcomes
after re-intervention are worse than primary interventions.
Table. Demographic variables and outcomes
Primary Recurrent P value
Gender (% male) 61 57 ns
Age (mean  SD; years) 65  12 58  11 ns
30-day mortality (%) 1 1 ns
Morbidity (%) 4 4 .05
Cumulative patency (% patent)* 95  2 83  2 .05
Restenosis (% free)* 87  3 61  5 .01
Clinical benefit (% retained)* 87  2 74  2 .05
*Mean  SEM at five years follow up.
Limb Ischemia During Femoral Cannulation for Cardiopulmonary
Support
Foley PJ, Morris RJ, Woo EY, Acker MA, Wang GJ, Jackson BM
Objectives: Extracorporeal membrane oxygenation and extracorporeal
cardiopulmonary support (ECMO/CPS) are potentially life-saving techniques
for patients with cardiopulmonary collapse. Complications include lower ex-
tremity ischemia from femoral cannulation. We examined the outcomes of
patients placed on ECMO/CPS, including the rate of limb ischemia.
Methods:All instances of ECMO/CPS over a three-year period (2006
to 2009) at a single university hospital were examined retrospectively for:
cannulation strategy, perfusion strategy, mortality, and limb ischemia. Po-
tential predictors of limb ischemia with femoral artery cannulation were age,
gender, body surface area (BSA), body mass index (BMI), and cannula size.
Results: Fifty-eight patients were placed on ECMO/CPS.Of these, 43
patients (74%) had femoral arterial cannulation. In 10 patients, the superfi-
cial femoral artery was cannulated prophylactically (without antecedent limb
ischemia), and perfused from a branch of the ECMO/CPS circuit. In seven
of the remaining 33 patients (21%), all male, limb ischemia developed,
requiring decannulation with fasciotomy (n  4) or additional cannulation
of the superficial femoral artery (SFA) with branching of the ECMO/CPS
circuit (n  3). One patient with ipsilateral leg ischemia required eventual
amputation. Patients with limb ischemia were significantly younger than
those who did not develop limb ischemia (P  .001). BSA, BMI, and
cannula size did not predict limb ischemia. Overall 30-day mortality follow-
ing the initiation of CPS/ECMO was 79%. There was no correlation
between limb ischemia and mortality.
Conclusions: Younger patients may be at increased risk for lower
extremity arterial insufficiency with femoral cannulation for ECMO/CPS.
Prophylactic or expectant SFA cannulation are reasonable approaches, and,
given that mortality does not increase with limb ischemia, SFA cannulation
from a branch of the circuit should be instituted liberally when required.
